Tag Archive for: Dupixent

The key opinion leaders (KOLs) interviewed by GlobalData have shared optimistic views on Dupixent, noting that its novel pathway presents anti-mucous effects, which is an additive value, supplementing its anti-eosinophil effects. KOLs have also communicated that the data presented in the clinical trials brings a great advantage to the asset and to the COPD space, perhaps even over other biologics in the COPD pipeline,” notes GlobalData Pharma Analyst Asiyah Nawab.

Today Sanofi and partner Regeneron won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster than the United States.

The company announced today that its drug, Rinvoq, for treating a type of inflammatory skin condition, was found to be more effective than Regeneron Pharmaceuticals and Sanofi’s Dupixent in a late-stage head-to-head study.

The FDA on Thursday greenlit the label expansion of AstraZeneca’s subcutaneous IL-5 receptor blocker Fasenra (benralizumab), which can now be used as an add-on maintenance treatment for severe eosinophilic asthma in children six to 11 years of age.

The FDA has granted Priority Review to Sanofi and Regeneron’s supplemental Biologics License Application seeking to expand its blockbuster antibody therapeutic Dupixent (dupilumab) into chronic obstructive pulmonary disease, the companies announced Friday.

Despite strong sales of its blockbuster drug Dupixent, Sanofi reported that its fourth-quarter 2023 operating income dropped 5% due to a weaker U.S. dollar, high expenses and generic competition.

The agency approved the use of Regeneron and Sanofi’s Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg.

The company plans to seek U.S. approval for its best-selling anti-inflammatory drug Dupixent to be used in the treatment of “smoker’s lung”, also known as COPD, after a second large trial showed significant benefits.

Today the company beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment, Dupixent.

The FDA’s schedule is picking up speed, with six target action dates over the next two weeks, including one for a blockbuster cancer treatment and another for a highly anticipated therapy for a rare pediatric disorder.